Mineralys Therapeutics (MLYS) Research & Development (2022 - 2026)

Mineralys Therapeutics has reported Research & Development for 5 years, with the latest figure at $24.4 million in Q1 2026.

• Quarterly Research & Development fell 35.68% year-over-year to $24.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $118.5 million (down 32.56% YoY) and the FY2025 annual result came in at $132.0 million, down 21.69% from the prior year.
• Research & Development steadied at $24.4 million in Q1 2026 per MLYS's latest filing, from $24.4 million in the prior quarter.
• Over five years, Research & Development peaked at $54.0 million in Q3 2024 and troughed at $5.6 million in Q2 2022.
• A 5-year average of $24.8 million and a median of $24.4 million in 2026 frame the typical range for Research & Development.
• The sharpest annual moves came in 2023 and 2025: Research & Development surged 271.33% in 2023, then plunged 45.25% in 2025.
• Over 5 years, Research & Development stood at $7.8 million in 2022, then jumped by 202.95% to $23.7 million in 2023, then jumped by 88.17% to $44.6 million in 2024, then slumped by 45.25% to $24.4 million in 2025, then fell by 0.15% to $24.4 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $24.4 million, $24.4 million, and $31.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.